NM_000432.4(MYL2):c.429C>G (p.Pro143=) AND not specified

Germline classification:: Likely benign (2 submissions)
Last evaluated:: Jan 21, 2023
Review status:: 2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV000036405.8

Allele description [Variation Report for NM_000432.4(MYL2):c.429C>G (p.Pro143=)]

NM_000432.4(MYL2):c.429C>G (p.Pro143=)

Gene:

MYL2:myosin light chain 2 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

12q24.11

Genomic location:

Preferred name:

NM_000432.4(MYL2):c.429C>G (p.Pro143=)

HGVS:

NC_000012.12:g.110911149G>C
NG_007554.1:g.14429C>G
NM_000432.4:c.429C>GMANE SELECT
NP_000423.2:p.Pro143=
NP_000423.2:p.Pro143=
LRG_393t1:c.429C>G
LRG_393:g.14429C>G
LRG_393p1:p.Pro143=
NC_000012.11:g.111348953G>C
NM_000432.3:c.429C>G
c.429C>G
p.Pro143Pro

Links:

dbSNP: rs374328118

NCBI 1000 Genomes Browser:

rs374328118

Molecular consequence:

NM_000432.4:c.429C>G - synonymous variant - [Sequence Ontology: SO:0001819]

Observations:

Condition(s)

Synonyms:: AllHighlyPenetrant
Identifiers:: MedGen: CN169374

Recent activity

Clear Turn Off Turn On

Polyneura latissima voucher GWS030821 ribulose-1,5-bisphosphate carboxylase/oxyg...
Polyneura latissima voucher GWS030821 ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit (rbcL) gene, partial cds; chloroplast
gi|1611811941|gnl|uoguelph|ABMMC171 .rbcL|gb|MH277309.1|

Nucleotide
Polyneura latissima voucher GWS021936 cytochrome oxidase subunit 1 (COI) gene, p...
Polyneura latissima voucher GWS021936 cytochrome oxidase subunit 1 (COI) gene, partial cds; mitochondrial
gi|733372390|gnl|uoguelph|ABMMC1212 COI-5P|gb|KM254894.1|

Nucleotide

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV000060060	Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	criteria provided, single submitter (LMM Criteria)	Likely benign (Apr 17, 2012)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]
SCV003800762	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	criteria provided, single submitter (LabCorp Variant Classification Summary - May 2015)	Likely benign (Jan 21, 2023)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV000060060

Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine

criteria provided, single submitter

(LMM Criteria)

Likely benign
(Apr 17, 2012)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

SCV003800762

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)

Likely benign
(Jan 21, 2023)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	not provided	2	2	not provided	not provided	not provided	clinical testing
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

A systematic approach to assessing the clinical significance of genetic variants.

Duzkale H, Shen J, McLaughlin H, Alfares A, Kelly MA, Pugh TJ, Funke BH, Rehm HL, Lebo MS.

Clin Genet. 2013 Nov;84(5):453-63. doi: 10.1111/cge.12257.

PubMed [citation]

PMID:: 24033266
PMCID:: PMC3995020

Details of each submission

From Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, SCV000060060.6

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	2	not provided	not provided	clinical testing	PubMed (1)

Description

Pro143Pro in exon 7 of MYL2: This variant is not expected to have clinical signi ficance because it does not alter an amino acid residue and is not located withi n the splice consensus sequence. This variant has been identified in 0.03% (1/37 38) of African American chromosomes from a broad population by the NHLBI Exome S equencing Project (http://evs.gs.washington.edu/EVS/) Pro143Pro in exon 7 of M YL2 (allele frequency = 0.03%, 1/3738) **

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	not provided	not provided	not provided	not provided		2	not provided	2	not provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV003800762.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Nov 3, 2024

ClinVar

Relating variation to medicine